Cadrenal Therapeutics Business Summary

Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical company operating on a pre-revenue business model focused on the development and future commercialization of novel anticoagulation therapies for rare and high-risk cardiovascular conditions. The company’s revenue strategy centers on advancing its clinical pipeline—headlined by tecarfarin (Phase 3-ready oral VKA), VLX-1005 (Phase 2 12-LOX inhibitor), and frunexian (Phase 2-ready Factor XIa inhibitor)—to achieve regulatory milestones that facilitate product sales, strategic licensing agreements, or milestone-based partnerships. Cadrenal’s primary business segments are dedicated to addressing critical gaps in the $40 billion anticoagulation market, specifically targeting underserved populations such as patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as those with left ventricular assist devices (LVADs) and heparin-induced thrombocytopenia (HIT). Direct competitors include Instil Bio, MiNK Therapeutics, and Tevogen Bio; however, Cadrenal occupies a distinct market niche by focusing on specialized indications where standard-of-care direct-acting oral anticoagulants (DOACs) and traditional warfarin are clinically inadequate or contraindicated. The leadership team is anchored by Founder, Chairman, and CEO Quang X. Pham, a prolific life sciences entrepreneur who previously founded Lathian Health and Espero BioPharma. He is supported by Co-Founder and CFO Matthew K. Szot, who brings extensive public-market financial expertise from his tenure as CFO of S&W Seed Company, and Chief Operating Officer Jeffrey Cole, a veteran of global pharmaceutical manufacturing and corporate development. In February 2025, the company significantly bolstered its clinical pedigree by appointing Dr. James J. Ferguson, III—formerly the Head of U.S. Cardiovascular Medical Affairs at Amgen—as Chief Medical Officer. The company’s strategic oversight is further reinforced by a board of directors that includes Dr. Lee Scott Golden, the EVP and CMO of PTC Therapeutics, who joined in December 2025. Notable institutional validation is evidenced by a strategic collaboration with Abbott Laboratories focused on the use of tecarfarin in LVAD patients, positioning the company as a specialized leader in the evolution of anticoagulation management.